SEARCH

Current Edition

Single-Use Technology in Cell and Gene Therapies: Transferable Lessons from the Bioprocessing Industry

The biopharmaceutical industry has experienced significant diversification, innovation and breakthroughs in recent years. For instance, gene and cell therapies in development can both treat diseases in new, more effective ways and address rare diseases for which treatment options have not previously been available. The Office of Tissues and Advanced Therapies (OTAT), a branch of the U.S. Food and Drug Administration, has more than 20 gene and cell therapies listed as approved, with nearly 1,000 gene therapy molecules active in the pipeline. Amber Sherrick at CPC Biopharma will focus on one of the most important but often overlooked decisions when developing a single-use-based process – the correct connection technology.